Alere (ALR) has been under a strong bear grip, hence the stock is down -8.21% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 7.92% in the past 1 week. The stock has risen by 7.98% in the past week indicating that the buyers are active at lower levels, but the stock is down -7.27% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 1.32% and the 50-Day Moving Average is 1.07%. Alere (NYSE:ALR): stock turned positive on Friday. Though the stock opened at $39.97, the bulls momentum made the stock top out at $40.5 level for the day. The stock recorded a low of $39.875 and closed the trading day at $40.45, in the green by 0.92%. The total traded volume for the day was 620,957. The stock had closed at $40.08 in the previous days trading.
The company Insiders own 1.93% of Alere shares according to the proxy statements. Institutional Investors own 93.23% of Alere shares. Also, Equity Analysts at the Brokerage Firm, BTIG Research, upgrades their rating on the shares of Alere (NYSE:ALR). BTIG Research has a Buy rating on the shares. Previously, the analysts had a Neutral rating on the shares. As per the latest report, the brokerage house announces the price target to $48 per share. The rating by the firm was issued on August 8, 2016.
Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics, patient self-testing, consumer diagnostics and, corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The patient-self testing segment provides services designed to provide physicians with actionable data that allow them to make decisions in real time, deliver care, and put the individuals they treat on a pathway to better health. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its 50/50 joint venture with The Procter & Gamble Company (P&G).